Vitality Watch

Dossier pubmed review 01-oct-2026
Narrative review or expert overview without new data

Mitochondria and associated complexes as therapeutic targets in aging: From biomacromolecular structure-function insights to clinical translation.

Key claim: Structural and functional disruptions of mitochondrial complexes (ETC, mPTP, and protein quality-control systems) drive cellular senescence and inflammaging, and targeting these assemblies is a promising therapeutic route against aging and age-related disease.

Abstract

Mitochondria and their biomacromolecular complexes-such as the electron transport chain (ETC), mitochondrial permeability transition pore (mPTP), and protein quality control systems-play pivotal roles in aging and age-related diseases. This review integrates recent insights into how structural and functional disruptions of these complexes drive cellular senescence and systemic decline. We outline the architecture of mitochondrial assemblies (e.g., oxidative phosphorylation (OXPHOS) complexes, mtDNA-protein interactions) essential for energy production and organelle stability. Age-related alterations in stoichiometry, conformational states (e.g., mPTP opening), and post-translational modifications (e.g., SIRT3-mediated acetylation) compromise mitochondrial integrity, fueling metabolic dysfunction and chronic inflammation (“inflammaging”). Therapeutic strategies include small-molecule stabilizers of ETC supercomplexes, peptide-based mPTP inhibitors, and CRISPR-mediated correction of mtDNA-protein mismatches. Tissue-specific models (e.g., Complex I in skin aging, Bcl-2 protein imbalance in ovarian aging) exemplify the clinical relevance. We also categorize nine age-associated diseases-neurodegenerative, cardiovascular, and cancer types-based on their dependence on distinct mitochondrial complexes, such as ATP synthase in cancer resistance and the TIM/TOM import machinery in Alzheimer’s disease. By linking structural findings (e.g., cryo-EM studies) with therapeutic innovation, this review offers a framework for targeting mitochondrial complexes to mitigate aging and its related pathologies.

Why this matters

Structural and functional disruptions of mitochondrial complexes (ETC, mPTP, and protein quality-control systems) drive cellular senescence and inflammaging, and targeting these assemblies is a promising therapeutic route against aging and age-related disease.

Source

Link

Briefing card

Mitochondria and associated complexes as therapeutic targets in aging: From biomacromolecular structure-function insights to clinical translation.
Stage: review · pubmed · 01-oct-2026

Structural and functional disruptions of mitochondrial complexes (ETC, mPTP, and protein quality-control systems) drive cellular senescence and inflammaging, and targeting these assemblies is a promising therapeutic route against aging and age-related disease.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.mito.2026.102221

build build 880 · 2bcef25 · 2026-11-18